Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Continued
You can bet your last ‘shilling’ that I am. Not only, will I make a ‘bob or two’, which is always an extremely attractive proposition for a ‘God’s Own Country’, Lad. But also, from an altruistic and personal perspective as when we are successful, this will vastly enhance the quality of life of so many people. Anything that can reduce extensive waiting for results and the associated psychological trauma will be a blessing. IMHO all the planets are aligning to produce a colossal outcome!
As the saying goes, patience is a virtue as is ‘DYOR’, good luck and stay well.
YB
This is not about Charlie and the Chocolate Factory (although I would not mind one), but the race in the UK is for, reliable, validated and approved, Covid-19 tests. The person who decides is not the eccentric chocolatier Willy Wonka, but BJ (who in the past may have been called eccentric himself) et al and the UK government.
'Crappy' tests to check for past coronavirus infection are flooding the US, lab association says: - "It's like the wild, wild West out there -- or wild East," said Scott Becker, a reference to the fact that at least half of the companies making these tests are in China.’
https://www.msn.com/en-us/news/us/crappy-tests-to-check-for-past-coronavirus-infection-are-flooding-the-us-lab-association-says/ar-BB12c01k
It is obvious that the competition is fierce in this sector to obtain the Golden Ticket and therefore, attain the UK governments and maybe the global outcome. There are some fantastic contributions to the discussion, however, some posters on this BB are posting (hopefully unintentionally) unreliable information/endorsements which I do find quite worrying. Not only from an investment but an altruistic perspective. One example is that a number may give the impression that if the ‘product’ displays a ‘CE mark’, this could imply that in some way it has received official UK approval and has been validated. Therefore, what does the CE mark mean? ‘By affixing the CE mark the Responsible Person takes on responsibility for the conformity of the product. CE marking is a visible sign that the product complies with all relevant product supply law, and its presence together with the, Declaration of Conformity, gives the product to which it is affixed presumption of conformity with relevant product safety Directives.’
‘However, the CE mark is not a quality mark, nor a guarantee that the product meets all the requirements of relevant EU product safety law.’
https://www.hse.gov.uk/work-equipment-machinery/ce-mark-summary.htm
‘The limits of testing kits: Even if a test has a CE mark, it may be of limited use.
Professor John Newton, national coordinator of the UK coronavirus (COVID-19) testing programme, has warned that some rapid tests could be misleading, by providing inaccurate or inconsistent results, potentially putting those tested and those around them at risk.’
https://www.gov.uk/guidance/guidance-on-coronavirus-covid-19-tests-and-testing-kits
Obviously, the required validation in the first instance is to achieve PHEs requirements. Therefore, (as some astute posters have already identified) no news can be good news as inflated claims can just obfuscate the situation. My limited (although I am following the science, as advised by the government) opinion, is ODX and the consortium continue to be front runners in achieving ‘PHE’ validation. Consequently, there may be a couple of ‘GTs’ up for grabs. Am I pleased that I’ve found and invested in one of the few companies with the unbelievable opportunity of holding one
Good day all. Further to my post of yesterday, I now realise that I should have included my reference for such a statement and can only apologise. I blame it on alcohol fuelled, ‘lockdown’ malady, although it prompted me to further my (already extensive) research on one of my significant investments.
So far there has been 3 patent documents submitted to the ‘Canadian Intellectual Property Office’.
https://www.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=Nuformix
As we already know, the 1st was issued last year.
Patent CA 2846460 English Title: ‘APREPITANT L-PROLINE COMPOSITION AND COCRYSTAL’. Applicants: NUFORMIX LIMITED (United Kingdom).
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2846460/summary.html?query=Nuformix&type=
However, most investors may not realise the 2nd (of 3) was Granted/Issued on 14/04/2020.
‘Patent CA 2892832 English Title: APREPITANT L-PROLINE SOLVATES - COMPOSITIONS AND COCRYSTALS’. Applicants: NUFORMIX LIMITED (United Kingdom).
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2892832/summary.html?query=Nuformix+&type=basic_search
The 3rd (of 3) is Application: CA 2908440 English Title: TRANILAST COMPOSITIONS AND COCRYSTALS. Applicants: NUFORMIX LIMITED (United Kingdom).
On 09/04/2020 this is still awaiting an ‘Amendment’.
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2908440/summary.html?query=Nuformix&type=
(Interestingly this is for ‘Tranilast Compositions’)
In addition to providing an update for constructive and perceptive posters, hopefully, it will also provide reassurance to the obfuscating negative posters, especially those who constantly criticise Dan and the BOD. As this indicates (during these trying times) its business as usually and valuable progress is being achieved, and I for one am not concerned, regarding the lack of formal communications from the company. As those who are professional/business savvy will know, negotiations/developments are industry sensitive and will be shared at the appropriate time. Ultimately, this should result in substantial rewards, not the few ‘pennies’ rise in SP that some investors are baying for now!
Good luck to all and stay well.
YB
Could be in the ‘East’ but perhaps look where the sun sets! Milestones equal funds, funds equal more developments and ultimately incredibly happy investors!
All the very best especially to the long-term holders who have kept the faith and stay well.
YB
Daily Mail Saturday May 9, 2020. Page 87
WHY SHOULD YOU INVEST?
John Meyer, head of research at SP Angel, said :
‘In Kenya the company operates in a remote location and is able to work through the coronavirus pandemic. And the closure of rival mines may serve to keep the market tight for some time.’
DYOR and keep well.
YB
Good afternoon B2HS2L(BH) and Walkingbear (WB) and many thanks for your posts. If I had to favour one side, it would be WB and would usually ask for the original poster (BH) to please clarify/justify their comments as to why they thought there had been non-disclosure/transparency by TRX. However, that is their personal choice, nevertheless it would appear BH comments may contradict one of his/her references posted at 00:39hrs: -
‘Go to page 6 of the above link, (AIM Rules for Companies March 2018):
General disclosure of price sensitive information
11) An AIM company must issue notification without delay of any new developments which are not public knowledge which, if made public, would be likely to lead to a significant movement in the price of its AIM securities.’
One could claim that it was placed (2017) in the ‘public domain’ (one of which is referenced) and was therefore ‘public knowledge‘ (further links are provided below), however tenuous they may appear. It was then disclosed (as previously referred to) in the company accounts, as required. However, although I am no expert, I thought I would add my ‘two-pennorth worth’ as I was a little discombobulated as to why it was ‘posted’ in the first place. The question I have is, how much transparency is enough, how much research can we perform and ultimately does this have a positive or negative impact on my continued investment!
https://www.medicaldevicesip.com/2017/05/10/lifenet-alleges-patent-infringement-against-tissue-regenix-and-community-tissue-services/
https://www.courtlistener.com/docket/6060453/lifenet-health-v-tissue-regenix-woundcare-inc/
https://dockets.justia.com/docket/texas/txwdce/5:2017cv01061/900048
https://www.pacermonitor.com/public/case/21390348/LifeNet_Health_v_Tissue_Regenix_Woundcare,_Inc_et_al
The answer to myself is, NO. Obviously, it is historic and therefore shouldn’t influence future progress and my faith has not diminished. Once funding has been secured, this will (along with one other investment) provide me with an extremely comfortable and worry-free retirement.
As they say, please, please DYOR and stay well
YB
Carados, excellent find and in my opinion is not just interesting, but a must watch. Obviously its quite a lengthy video, but for me intriguing in that it dismisses some of the alleged science and possible myths that are out there. Negative posters on here may not be enamoured with some of the content, as it may not fit in with their de-ramping views. However, it is extremely supportive of (not necessary ‘lab’ but ‘rapid at point of contact’) testing, which bodes extremely well for ODX and our developments.
https://www.youtube.com/watch?v=xfLVxx_lBLU&feature=youtu.be
Good luck all and keep well.
YB
Can you please justify why you posted such an obfuscating statement ‘Potentially a killer blow to ODX/Mologic if true’!
Unfortunately, I cannot find any research evidence why this would affect the company’s development/future. Therefore, I would very much appreciate being signposted to such before, I make any further decisions on my investment strategy.
I thank you in anticipation or are you just being disingenuous?
Good luck all, stay safe and keep well.
YB
Good morning SD78, unfortunately, I missed your post on 03 March 2020 17:47, but had a look back and you said:
Had a quick look back and couldn't see any conversation around this patent from 20th Feb, but apologies if I've missed it. Trying to figure out the background, but the below patent assigned to NFX was published on 20 Feb 2020. Looks like a new filing relating to their cocrystal use of Tranilast. It was filed in August last year.’
You are quite right it was a new filing in 08/2019, which appears to be the initial foundation for the Kissie collaboration. Unfortunately, the process takes time, is intense and quite rightly so, as due diligence is crucial. The 2020-02-20 Publication of WO2020035546A1 is acknowledgement/confirmation that the patent now has ‘World Rights’. Although I cannot be sure, but this may have been a contractual requirement for the ‘collaboration’ to progress.
Unfortunately, certain ‘things’ cannot be shared outside of any business negotiations due to confidential sensitivity. Obviously, this means that some shareholders become frustrated and, in some instances, disillusioned. As the saying goes ‘Rome wasn’t built in a Day’ and as I said yesterday ‘even if for some astonishing reason it does not happen, at least we retain rest of the world rights and NFX are not just a ‘one trick’ pony.’ I personally feel that NFX is my pension fund and will provide me with an extremely comfortable retirement. However, as the saying goes; patience is required and please, please do your own research. Do not just rely on the advice of investors (although there are some excellent posters) on BB’s, myself included.
Good luck all, stay safe and keep well.
YB
Fibrosis is a condition that can affect most organs of the body and fibroblast
proliferation, differentiation, and collagen synthesis are known to be key factors in the progression of
most types of fibrosis. Tranilast has been shown in-vivo to have potential beneficial effects in
numerous fibrotic conditions. Tranilast has been shown in-vivo to have potential in lung fibrosis (M.
Kato. Eur RespirJ. 2013; 42(57): 2330), kidney fibrosis (DJ Kelly,JAm Soc Nephrol. 2004; 15(10):
2619-29), cardiac fibrosis (J Martin, Cardiovasc Res. 2005; 65(3): 694-701), ocular fibrosis (M J Moon,
BMC Opthalmol. 2016; 16: 166) and liver fibrosis (M Uno, Hepatology. 2008; 48(1): 109-18.
‘[006] Given the wide range of fibrotic conditions and cancers for which tranilast could have a potential therapeutic benefit, as well as the different patient types and specific areas of the body requiring treatment, it is anticipated that patients would benefit from having multiple delivery methods for the administration of tranilast so as to best suit the patient's needs. The pharmaceutical compositions could include, for example, a solid oral dosage, a liquid oral dosage, an injectable composition, an inhalable composition, a topical composition or a transdermal composition.’
https://patents.google.com/patent/WO2020035546A1/en?inventor=Joanne+Holland&assignee=Nuformix+Limited
I hope this provides some reassurance for those few cynics amongst us and even if for some astonishing reason it does not happen. At least we retain rest of the world rights and as we all know NFX are not just a ‘one trick’ pony.
Good luck all, stay safe and keep well.
YB
The info below is the patent WO2020035546A1 and is the legal foundation for the exciting and extremely lucrative collaboration between Nuformix and Kissei Pharmaceuticals. Therefore, when the i(’s) are dotted and the t(‘s) are crossed and the signatures are drying, this will soar. Unfortunately, further patience may be required especially due to the travel restrictions etc due to the virus crisis and I’m not sure whether electronic signatures would be accepted. I have tried contacting ‘Mystic Meg’ to predict a timeline, but alas I was unsuccessful due to her socially isolating.
Crystalline tranilast salts and their pharmaceutical use
Worldwide applications
2019 WO
Application PCT/EP2019/071881 events
2018-08-14 Priority to US201862718563P
2018-08-14 Priority to US62/718,563
2019-08-14 Application filed by Nuformix Technologies Limited
2020-02-20 Publication of WO2020035546A1
(Patent Cooperation Treaty)
‘Abstract
The invention relates to crystalline tranilast salts. The crystalline tranilast salts, their preparation and their characterization are described and shown in the figures. The invention relates to pharmaceutical compositions containing a crystalline tranilast salt of the invention and a pharmaceutically acceptable carrier. The invention also relates to methods of treatment and the use of a therapeutically effective amount of a crystalline tranilast salt of the invention for treatment. The invention also relates to a method of preparing a liquid pharmaceutical composition comprising the step of dissolving a crystalline tranilast salt of the invention in a pharmaceutically acceptable solvent and to liquid pharmaceutical compositions prepared according to that method.’
Tranilast has been marketed in Japan, China and South Korea by Kissei Pharmaceutical Co. Ltd, for
allergic conditions such as allergic conjunctivitis, bronchial asthma, allergic rhinitis and atopic
dermatitis, under the Rizaben® brand name for more than thirty years. More recently tranilast has
also been shown to have anti-proliferative properties. Tranilast was shown to inhibit the
proliferation of fibroblasts and suppress collagen synthesis (M. Isaji. Biochem Pharmacol. 1987; 36:
469-474) and also to inhibit the transformation of fibroblasts to myofibroblasts and their subsequent
contraction (M. Isaji. Life Sci. 1994; 55: 287-292). This additional behaviour led to tranilast gaining
additional approval for the treatment of keloids and hypertrophic scars.
[004] Over recent years many researchers have explored the anti-proliferative effects of tranilast
to assess its potential in fibrotic and cancerous conditions. Its anti-proliferative action is believed to
be due to its ability to inhibit transforming growth factor beta (TGF-ß) (H. Suzawa. Jpn J Pharmacol.
1992 Oct; 60(2): 91-96).
To be continued
When ODX and their co-collaborators produce a successful (at point of contact, not lab reliant) instant AB test. Then this will be humongous, not only fiscally for those invested, but altruistically and essential for a return to global ‘normality’. In addition, for those who have been sharing their recent clinical experiences this may be off interest.
There Are Asymptomatic Patients
‘As regards the symptoms, even if you have experienced coronavirus symptoms, you are not necessarily immune to the deadly virus. This is because until you get tested, you will never be sure if your symptoms are COVID-19 related or brought about by seasonal flu. In fact, early symptoms of COVID-19 can be easily mistaken for many types of winter bugs, including colds and flu. There are also many cases where people are COVID-19 positive, yet they do not develop any symptoms or feel unwell.
According to Dr. Li QinGyuan, while there are those infected who developed a protective antibody, they are not sure how long the protection lasts. Dr. Li is the director of pneumonia prevention and treatment at China-Japan Friendship Hospital’.
https://www.ibtimes.com/coronavirus-tips-do-you-already-have-immunity-once-youve-been-infected-2945485
For those who are interested in the science and not just the potential monetary returns that investment in ODX might bring. Then the ‘British Society for immuniology’ expands upon this: -
https://www.immunology.org/public-information/bitesized-immunology/pathogens-and-disease/immune-responses-viruses
Good luck all, stay safe and keep well.
YB
Just read the RNS and finally got my answers. Should have looked earlier and it would have saved me composing my last post. Unfortunately the RNS wasn't advertised on my web page and I only realised when I started reading the most recent posts.
GLA
Krautyankee totally agree with your post. Have been undecided whether to reinvest in MTFB and posted yesterday (13th April 11:49) requesting advice/help in answering certain questions. Unfortunately, none has been forthcoming, therefore, I can only surmise that there are no positive answers.
Another question, why hasn’t MTFB etc, jumped on the bandwagon and constructively manipulated their relationship/collaboration with ‘Lamellar Biomedical’. This is a great opportunity for them and if they did, the share price would soar. One might ask, does the collaboration continue to exist!
Moneymunch (today 10:13) states ‘it also in preclinical trials since October with the US Army WRAIR’. If he had visited:- https://adisinsight.springer.com/drugs/800018080 (Most Recent Events Section) he would, have seen the following;
31 Oct 2019 Motif Bio entered into research agreement with Walter Reed Army Institute of Research to conduct preclinical testing
08 Nov 2019 Motif Bio plans a preclinical study for wound infection
18 Mar 2020 Motif Bio ceased all its operations and sold its assets
I don’t have a problem with posters having their own opinions and sharing their views. But if they ramp without evidence and investors lose money (although no one makes a person invest) then they must live with their conscience (if they have one).
IMHO it would appear that this is being ‘ramped’ beyond belief without genuine evidence. Please re-read Krautyankee (10:08) post. Research, Research and Research again, don’t get ‘sucked’ in by the few.
I, like ‘Ivyspivey’ and many others, lost heavily on the St Valentine’s Day massacre and ultimately sold out of this reprehensible company (a few months ago) with a substantial loss. I am not trying to rain on anyone’s parade and believe it or not, would love to see some of the LTH recover some of their losses and for the many sufferers of this terrible virus have a viable treatment. In fact, I actually thought about reinvesting last Thursday, but then stood back and as the song goes; https://www.bing.com/videos/search?q=once+bitten+twice+shy&view=detail&mid=5BADAF2EE97CA1648A0A5BADAF2EE97CA1648A0A&FORM=VIRE0&PC=LCTS&cc=GB&setlang=en-GB&PC=LCTS&cvid=f9dd9beec5954bffb66eb5c34b5e849e&qs=LS&nclid=60F1C024A8D17225C3FA9FA8215AEBE3&ts=1586772505365
Thought don’t get sucked in and get bitten again, consequently try and do some further (as we are always being advised) research but haven’t had much luck. The following list isn’t extensive, but if anyone can help me, I would be eternally grateful: -
Has anyone seen/heard of any communication relating to the ‘the collaboration between MTFB and Lamellar Biomedical’ since it was announced back in May 2019’?
Has there been any information (official or otherwise) regarding the proposed ‘in vivo pre-clinical study evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections’?
Is there any material/reference to the partnership/collaboration on ‘Lamellar Biomedical Ltd’ website or has there been any previous reference on Motif Bios website?
If not, why not?
For those who are interested, I did come across the following regarding ‘The agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology’.
RNS Number: 9200Q Motif Bio PLC, 24 October 2019
Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology.
https://adisinsight.springer.com/drugs/800018080
Although, without proof that they are still in a substantive partnership I am still hovering. I thank you in anticipation and keep safe, GLA.
Soupdragon78 unbelievable coincidence, although, he may just have had a lapse of memory. They do say that certain conditions affect short term memory, although (if it is him) it must be an extreme issue. Aprox 2hrs ago Trader…@Eagle _Trader01 (London, England Joined September 2017,185 Following 31 Followers) posted: - #NFX Hearing RNS is getting typed up. Get ready for the Japan Deal BOOOOOM.
https://twitter.com/Eagle_Trader01/status/1247834360646176769
By the way good moves, which one is you. If this is not you, my apologies if it is, please, don’t lie and at least have the guts to own up!
I can not complete this post without referring to ‘oldblue1973’ post at 08:42 ‘ok think about this....this was probably some guys last chance of beating prostate cancer and apparently this stuff actually works now because off your sack the board rubbish the trails been halted.....now there is probably some boy or girl out there who has been balling there eyes out because they have been told there fathers last chance at cancer has been stopped
I hope you all happy’
Unfortunately, this is a very imprudent comment, as he has not considered the stage of Val201 development, which obviously means at this time no one can benefit by Val201. Obviously, he must not only be discombobulated, but oblivious to the psychological damage his statements can cause, if he is spreading such rumours.
I truly believe change must happen.
Have a good w/e and GLA
It is very rare that I would be critical of any members post or opinion on any BB as I believe every person has the right to their own views. People usually invest in bio companies for financial/ altruistic reasons or both and these should be respected. However, in my opinion the situation on here is extremely divisive (which is not a problem), but they are becoming more emotive and illogical (not researched based) and without relevant reference to fact.
The fact is Valirx has just completed (Actual Primary Completion Date: January 27, 2020)
a phase I/II clinical trial (Study Start Date October 2014) for Val201.
A Phase1/11 clinical trial is a study that tests the safety, side effects, and best dose of a new treatment. Phase I/II clinical trials also test how well a certain type of cancer or other disease responds to a new treatment. In the phase II part of the clinical trial, patients usually receive the highest dose of treatment that did not cause harmful side effects in the phase I part of the clinical trial. Combining phases I and II may allow research questions to be answered more quickly or with fewer patients. Also called phase 1/phase 2 clinical trial.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/phase-i-ii-clinical-trial
It has taken over 5 years for completion of this initial phase and, only enrolled 18 participants when they were estimated to enrol 25 participants. To date ‘No Study Results have been posted for this Study’.
https://www.clinicaltrials.gov/ct2/show/results/NCT02280317?term=NCT02280317&cond=Cancer&draw=2&rank=1
If they can achieve ‘proof of concept’ and regulatory approval for continuation into phase III clinical trials, what will be required and how long will it take? On the 18th December 2017 it was stated, (VAL201 is currently in Phase I/II clinical trials at UCLH for prostate cancer.), the company now needs phase II studies with a reasonable number of patients after a good dose ranging result to attract big name pharmaceutical interest to pay for the expensive phase III clinical trials.
https://contrarianinvestor.net/posts/2017/12/18/valirx-moves-up-sharply-on-news-that-regulator-will-allow-dose-ranging-study-for-val201
Who will fund this expensive and time consuming phase? Regarding Dr George Morris stating, that he will not seek re-appointment as a director of the Company following the completion of the VAL201 trial and its regulatory approval, does he mean Phase I/II or ultimate completion. If it’s the later, he will be a director for a very long time. In addition, I know that there have been repetitive statements regarding the competence of the Bod. I can only state that if I had performed (during my 49 years of professional responsibility) with such dereliction of duty and little understanding and appreciation of my ‘duty of care’. I would not have been employed for very long, but would also be void of any compassion.
Cont
Non-automatic licenses are a trade administration procedure "fully compatible with the rules of the World Trade Organization (WTO), which sets a period of 60 days in which the Industry Secretariat must be issued so that this request does not respond to speculative manoeuvres. "
The government analysed in the last hours that when President Alberto Fernández took office, oil was trading at US $ 63 a barrel and began a rise to exceed US $ 70 in January, to face a drop below US $ 60 and enter the sharp decline in recent days to touch US $ 32.
"This volatility is a problem to think about investing in a sector with great oil potential but with different costs than the Middle East," said Kulfas.
Regarding the possibility of implementing the so-called "Creole barrel", the minister said: "We are not Saudi Arabia in our cost structure, and we have to think about how we locate a price that is not shot at us and is reflected in the pump."
"But neither can we accompany a very sharp drop that causes many wells to go out of production, losing jobs in oil and in the entire service industry associated with activity throughout the country," he added.
Finally, he assured that the government observes oil and gas "not as a merely extractive activity, but behind it is a large chain of suppliers, from national SME industries throughout the country that produce equipment and provide services generating a lot of employment", for which acts "as a lever for the long-term development of the Argentine economy".’
https://www.telam.com.ar/notas/202003/439500-gobierno-nacional-licencias-no-automaticas-importacion-hidrocarburos-crudo-gas-oil-nafta.html
GLA
YB